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indicate that MSC has both stimulating and suppressive actions
on experimental neoplasms. We have shown previously that a
single MSC administration to tumor-bearing animals has an
oncomodulating effect on the growth of tumors. Short-term stim-
ulation of the growth of tumor nodes initially after the MSC
injection was usually followed by subsequent deceleration of
their growth.
Here, we have studied the effects of allogeneic MSC on sar-
coma M-1 in rats. On day 11 after the sarcoma M-1 implantation,
1.5 million MSC grown from the bone marrow cell population of
Wistar rats was administered into the tail vein of outbred rats
from the experimental group. On days 17 and 30 of the tumors
growth, 10 rats from each group were used to study the sarcoma
M-1. To analyze the MSC distribution and localization in the
tumor parenchyma, on days 11 and 13, five rats in the study were
intravenously infused 2 million MSC, labeled in vitro by bromod-
eoxyuridine (BrdU). The techniques for studying of the tumor
reaction on the systemic MSC transplantation included
immunostaining for PCNA, BrdU and PECAM-1, in conjunction
with computerized analysis of the microscopic images.
One day after transplantation, the BrdU-labeled MSC localized
in the perivascular areas of angiogenesis on the periphery of
tumor nodes with the diameter of more than 6 mm, containing
foci of spontaneous necrosis. Sometimes, labeled cells could be
seen near the vessels situated deep in the tumor parenchyma.
On day 3, cells with the low-intense BrdU immunostaining were
found only rarely and mostly perivascularly. These cells were
visualized in the region of pericytes’ localization, and the low
BrdU-immunostaining intensity of their nuclei indicated the label
dilution effect.
Six days after the MSC administration, some local areas of the
connective tissue enlargements on the periphery of tumor nodes
were observed with a distinct vascular ingrowth into the tumor
parenchyma. In the same areas, the marginal region of tumor
nodes contained a considerable number of neutrophils and lym-
phocytes. The PCNA staining revealed foci of increased prolifera-
tive activity of tumor cells in these areas, as well as intensive
proliferation of fibroblasts and vascular endothelium, which
indicates the increase of angiogenesis and stroma formation.
After the MSC administration the content of parenchyma with
PCNA-positive nuclei significantly increased, whereas the volume
fraction of the necrosis regions decreased by more than 1.5 times.
On day 30 of the sarcoma M-1 growth, tumors in the experi-
mental group rats were surrounded by layers of connective tissue.
The peritumoral area was infiltrated by numerous lymphocytes
and macrophages. In the terminal period of the sarcoma growth,
the most quantitative parameters for tumors in the experimental
group did not significantly differ from the data obtained in the
control group. Only the rate of tumor cell apoptosis in animals
with transplanted MSC was statistically higher than that in
control rats.
Reviewing the literature regarding the influence of MSC on the
malignant growth revealed that this problem still remains quite
unclear and disputable. One of the contradictions is their ability
to have opposite effects on the repopulation activity of tumor
cells. The complex interactions between MSC, tumor microenvi-
ronment and neoplastic cells seem to be crucial for the outcome
of the oncological process development. Further detailed studies
of the mechanisms of the cellular therapy using MSC on carcino-
genesis are necessary to generate new insights into this area.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.120
P34
Plasma micro-RNAs as noninvasive biomarkers for diagnostics of
lung cancer
I. Zaporozhchenkoa,*, E. Morozkina,b, T. Skvortsovaa, E. Rykovaa,
A. Ponomarevac, N. Cherdyntsevac, E. Polovnikovb, O. Anikeevab,
O. Pashkovskayab, V. Vlassova, P. Laktionova,b. a Institute of Chemical
Biology and Fundamental Medicine SB RAS, Novosibirsk, Russian
Federation, bTomsk Cancer Research Institute, Tomsk, Russian
Federation, cAcademician E.N. Meshalkin Novosibirsk State Research




Lung cancer (LC) is currently the world’s leading cause of
cancer-related mortality with overall mortality to incidence ratio
of 0.87. Only 15% of LC patients are diagnosed at early stage of dis-
ease and have 5-year survival rate of 54%, whereas 56% of
patients have distant metastases and 5-year survival rate of about
4%. Current methods of lung cancer diagnostics are not efficient
as screening tools due to high costs (CT), low sensitivity and
health risks (radiology), invasiveness (biopsy) or low prevalence
in population (genetic alterations). New strategies for preclinical
lung cancer screening as well as monitoring of post therapy
relapses are required. MiRNAs circulating in blood were shown
to reflect the progression of disease and are thus considered as
potential biomarkers for cancer diagnostics and theranostics.
In this study we investigated seven-miRNA signature circulat-
ing in plasma of lung cancer patients and healthy individuals. All
sevenmiRNAswere previously shown to be involved in either reg-
ulation of cell cycle and apoptosis and/or tumor development,
invasion and vascularization.
Blood samples of 50 healthy individuals were obtained from
Center of New Medical Technologies (Novosibirsk, Russia) and
Novosibirsk Research Institute of Circulation Pathology of E.N.
Meshalkin (Novosibirsk, Russia). Samples of 75 lung cancer
patients, including 52 patients with squamous cell carcinoma
(SCC) and 18 patients with adenocarcinoma (AC) were obtained
from Novosibirsk Research Institute of Circulation Pathology of
E.N. Meshalkin (Novosibirsk, Russia) and Tomsk Cancer Research
Institute RAMS (Tomsk, Russia). None of the patients have under-
gone surgical treatment or received chemotherapy prior to blood
collection. Lung biopsy specimens and imaging techniques were
applied to confirm the histopathological features and tumor
stages of LC patients. Study was approved by ethical committees
of all participating organizations and written informed consent
was provided by all participants.
Circulating miRNAs were isolated from blood plasma using a
single-phase phenol-free protocol (Zaporozhchenko et al., Anal
Biochem, 2015; Rus. patent application No. 2014137763, priority
date 17.09.2014). Concentrations of miRNAs (miR-21, miR-19b,
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miR-126, miR-25, miR-205, miR-183, miR-125b) were measured by
qRT-PCR and normalized to miR-16.
Concentrations of four miRNAs (miR-19b, miR-21, miR-25,
miR-183) were significantly different in lung cancer versus
healthy individuals (p<0.05, T-test, two-sided). Two miRNAs were
upregulated (miR-19b, miR-21), two were downregulated (miR-25,
miR-183) in cancer patients. Four miRNAs (miR-19b, miR-126,
miR-25, miR-205) were found to be differentially regulated in
SCC patients when compared to healthy controls. In AC patients
only two miRNAs (miR-19b, miR-183) were differently expressed.
Thus, cancer subtypes have different input into overall picture.
Receiver Operating Characteristic (ROC) curve analysis of dif-
ferentially expressed miRNAs in total study population and
subtype-based groups showed that miR-19b has highest predic-
tive value for total population and SCC patients, while miR-183
was more effective in discriminating patients with AC. All miR-
NAs except miR-21 showed strong bias towards one of the
subtypes. Presumably a combination of miRNAs with opposite
bias should provide a more potent diagnostic tool for cancer
detection in total population than individual miRNAs or panels
of miRNAs that are specific to one cancer subtype. Indeed,
stepwise binary logistic regression has identified the combination
of miR-19b and miR-183 to be a strong prediction of disease in
total population and yielded a solid increase in AUC: 0,990
(miR-19b+miR-183) versus 0,806 (miR-19b) or 0,924 (miR-183). This
combination can be used to identify lung cancer with 94.7%
sensitivity and 95.2% specificity.
Thus, biological aspects such as tumor genetics and pheno-
type, stage of disease, response to therapy, and other meaningful
tumor properties of such heterogeneous malignancies as LC can
interfere with contents and composition of cell-free miRNA pool.
Wide profiling of circulating miRNAswill specify biomarkers of LC
phenotypes and improve non/less-invasive LC diagnostics.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.121
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The development of individual medicine is a very important
part of the whole health care system and especially of the oncol-
ogy patients’ treatment. The predictive markers could help to
prevent the development of the different diseases. Individual risk
assessment is based on the study of polymorphisms in genes
specific to different pathologies, especially those with a signifi-
cant social impact, such as lung cancer.
Like many other cancers, lung cancer is a multi-factorial
disease. The tumor suppressor genes are important in its patho-
genesis. One such very important gene is TP53, which encodes
the p53 tumor suppressor protein. It regulates the activation of
specific cellular processes and signaling pathways involved in
regulation, recognition of signals inside the cell, coordination of
metabolic processes, genome repair, cell division and death
(apoptosis), and interactions between cells. Insufficient produc-
tion or property modification of this protein leads to the develop-
ment of serious diseases, including lung cancer.
The TP53 gene has a number of polymorphic markers; the
Arg72Pro and the Gln157Lys markers are very important in case
of lung cancer. They are located in the DNA-binding domain of
TP53 at exons that play essential structural and chemical roles
in the contact between the p53 protein and specific DNA
sequences that constitute the p53 response elements. These
mutations result in a significant loss of DNA-binding activity
and transactivation capacity (P. Hainaut and M. Hollstein, 2000).
We studied the association of polymorphic markers Arg72Pro
and Gln157Lys of TP53 gene with the risk of nonsmall cell lung
cancer (NSCLC) in patients from the Moscow region. Our study
included 88 patients with NSCLC, 160 healthy persons as a control
for Arg72Pro and 60 healthy persons as a control for Gln157Lys.
We used PCR-RLFP analysis to identify the alleles of the polymor-
phic markers.
We observed higher frequencies of the markers predisposition
genotypes in group of patients then in control group. The distri-
bution frequency of Pro/Pro genotype Arg72Pro marker was
0.307 in the group of patients and 0.075 in the control. For the
Gln157Lys marker the Lys/Lys genotype was not observed. The
frequency of Gln/Lys genotype Gln157Lys marker was 0.377 in
patients and 0.106 in the control. We found the association of
both markers with the risk of NSCLC development. The genotype
Pro/Pro of Arg72Pro marker showed the increasing of NSCLC risk:
OR = 5.46, p = 8  106. The presence of Gln/Lys genotype of
Gln157Lys marker also led to increased risk of cancer develop-
ment: OR = 5.10, p = 0.002.
Our results suggest the importance of studied polymorphic
markers for risk of NSCLC assessment. The status of the Arg72Pro
and the Gln157Lys markers of TP53 gene can serve as an indepen-
dent prognostic indicator in this type of cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.122
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Background: There is increasing evidence that BRCA1-related
DNA-repair defects determine sensitivity to certain agents, such
as platinum-based chemotherapy. There is a lot of evidence about
a link between TNBC and BRCA1 deficiency. Many clinical
characteristics and molecular features are shared by sporadic
triple-negative breast cancer and BRCA1-associated breast
cancer. The majority of BRCA1-related breast cancers are of
basal-like/triple-negative phenotype. Identification of specific
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